Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is showing signs of a transitional period as it focuses on operational discipline and commercial reacceleration. Despite modest annual growth, the company's fourth quarter financial results were weaker due to underperformance in the US market. However, the recent cost restructuring and improved margins, along with a secured credit facility, indicate a positive step towards stabilizing operations and achieving sustainable profitability in the future.

Bears say

Pulmonx is facing multiple risk factors that could negatively impact its future financial performance, such as potential clinical or regulatory setbacks, partnership and financial risks, and market share risk. The company's Q1 results were disappointing due to a decline in U.S. sales and the absence of China sales, and its full-year revenue guidance is below expectations. Furthermore, Pulmonx has a history of consistent losses and significant cash burn, which raises concerns about its long-term financial sustainability.

Pulmonx (LUNG) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Pulmonx (LUNG) has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.